Bayer Presents P-III (QUANTI CNS) Trial Data of Gadoquatrane at European Congress of Radiology 2025
Shots:
- The P-III (QUANTI CNS) trial assessed GBCA gadoquatrane (0.04mmol Gd/kg) vs macrocyclic GBCAs (0.1mmol Gd/kg) in adults (n=305) with confirmed or suspected CNS pathologies undergoing contrast-enhanced MRI
- Study showed non-inferiority (1EP) & superiority across all visualization criteria (contrast enhancement, delineation, & morphology), plus higher sensitivity & specificity (2EP) for lesion detection & exclusion
- QUANTI program incl. 2 P-III trials: QUANTI CNS & QUANTI OBR (other body regions) for adults as well as QUANTI PEDIATRIC study in pts (birth to 18yrs.) for other body regions. Data of QUANTI OBR & QUANTI PEDIATRIC to be presented in future meetings with global regulatory filings underway
Ref: Bayer | Image: Bayer
Related News:- Bayer Submits MAA of Finerenone to Japan’s MHLW for Heart Failure (HF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
